You just read:

Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly's Third-to-Market Emgality to Second Place in the Anti-CGRP Class ― Surpassing Teva's Ajovy

News provided by

Spherix Global Insights

Sep 26, 2019, 08:36 ET